This article is more than 5 years old. Information may no longer be current.
CMS issues payment information for biosimilar Inflectra
Click Here to Manage Email Alerts
CMS has included payment information for Inflectra, the FDA-approved biosimilar to Janssen’s Remicade, in its January Average Selling Price pricing file, Pfizer announced.
The FDA approved infliximab-dyyb (Inflectra, Celltrion) in April 2016. It is the second biosimilar to be approved in the U.S., the first biosimilar to infliximab (Remicade, Janssen), and the first biosimilar monoclonal antibody available in the U.S.
The ASP pricing took effect January 1, 2017, and the MLN Matters Article Number MM9930 contains additional claims processing information, according to a press release.
Pfizer began wholesale shipment of Inflectra in the U.S. on November 21, 2016, which can currently be ordered from several national and regional wholesalers. The company said it is working with other distributors to achieve broad availability to patients and health care providers in the U.S.
Inflectra is priced at a 15% discount to Remicade’s current wholesale acquisition cost, which does not include discounts to payers, providers, distributors or other purchasing groups, according to the press release. Pricing for 340B hospitals has also become available.
Pfizer has also announced the launch of a reimbursement service and patient support program that provides coding and reimbursement support for providers, co-pay assistance to eligible patients with commercial insurance, and financial assistance for eligible patients who are uninsured and underinsured, according to the press release.